These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1325 related articles for article (PubMed ID: 30788621)
1. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621 [TBL] [Abstract][Full Text] [Related]
2. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478 [TBL] [Abstract][Full Text] [Related]
3. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions. Martens P; Lambeets S; Lau CW; Dupont M; Mullens W Acta Cardiol; 2019 Apr; 74(2):115-122. PubMed ID: 29909743 [TBL] [Abstract][Full Text] [Related]
4. Insights into implementation of sacubitril/valsartan into clinical practice. Martens P; Beliën H; Dupont M; Mullens W ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879 [TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction. Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035 [TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study. Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909 [TBL] [Abstract][Full Text] [Related]
7. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients. Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930 [TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review. Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802 [TBL] [Abstract][Full Text] [Related]
9. The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Sections of the Polish Cardiac Society. Grabowski M; Ozierański K; Balsam P; Dąbrowski R; Farkowski MM; Gackowski A; Jędrzejczyk-Patej E; Kalarus Z; Leszek P; Nessler J; Sterliński M; Opolski G; Przybylski A Kardiol Pol; 2019 Oct; 77(10):987-993. PubMed ID: 31527563 [TBL] [Abstract][Full Text] [Related]
10. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342 [TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274 [TBL] [Abstract][Full Text] [Related]
13. Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure. Nishihara Y; Nishimori M; Sawa T; Uemura K; Nagai S; Todo S; Oota E; Odajima S; Takeuchi K; Ichikawa Y; Kintsu M; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Shimizu M; Hirata KI; Tanaka H Heart Vessels; 2024 Feb; 39(2):95-104. PubMed ID: 37733071 [TBL] [Abstract][Full Text] [Related]
14. A narrative review on sacubitril/valsartan and ventricular arrhythmias. Wei Z; Zhang M; Zhang Q; Gong L; Wang X; Wang Z; Gao M; Zhang Z Medicine (Baltimore); 2022 Jul; 101(27):e29456. PubMed ID: 35801732 [TBL] [Abstract][Full Text] [Related]
15. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651 [TBL] [Abstract][Full Text] [Related]
16. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956 [TBL] [Abstract][Full Text] [Related]
17. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Curtain JP; Jackson AM; Shen L; Jhund PS; Docherty KF; Petrie MC; Castagno D; Desai AS; Rohde LE; Lefkowitz MP; Rouleau JL; Zile MR; Solomon SD; Swedberg K; Packer M; McMurray JJV Eur J Heart Fail; 2022 Mar; 24(3):551-561. PubMed ID: 34969175 [TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder. Monzo L; Lanzillo C; Tota C; Lino S; Fusco A; Minati M; Martino A; Calò L Curr Med Res Opin; 2019 May; 35(sup3):3-6. PubMed ID: 30894032 [TBL] [Abstract][Full Text] [Related]
19. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581 [TBL] [Abstract][Full Text] [Related]
20. Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples. Carluccio E; Dini FL; Correale M; Dattilo G; Ciccarelli M; Vannuccini F; Sforna S; Pacileo G; Masarone D; Scelsi L; Ghio S; Tocchetti CG; Mercurio V; Brunetti ND; Nodari S; Ambrosio G; Palazzuoli A; Clin Res Cardiol; 2024 Jun; 113(6):856-865. PubMed ID: 37733084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]